What is the current stock price of Kane Biotech Inc. (KNBIF)?

As of the latest market data, Kane Biotech Inc. (KNBIF) is trading at $0.02. The stock has seen a loss of 0.00% today.

Does Kane Biotech Inc. (KNBIF) pay a dividend?

Based on current data, Kane Biotech Inc. does not have a confirmed active dividend policy.

What is the market cap of Kane Biotech Inc.?

The current market capitalization of Kane Biotech Inc. (KNBIF) is approximately unavailable.

KNBIF

Kane Biotech Inc.·Healthcare

0.02

0.000%(+0.00)

Close Price

0.03

15.596%(+0.00)

Pre-Market

Last Updated: — ET

52W L: $0.0252W H: $0.05

KNBIF NEWS

globenewswire.com

1d ago

Kane Biotech Announces the Oversubscription and Closing of Private Placement Offering

Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 26, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces that today it has increased the size of its previously announced non-brokered private placement offering (the “Offering”) of units of the Company (“Units”) from up to $1,000,000 to $1,160,000 and has subsequently completed such Offering. The increase in the size of the Offering was driven primarily by outside investor demand.

globenewswire.com

May 13

Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress

Case study presented highlighted clinical experience with revyve® in complex wound care Case study presented highlighted clinical experience with revyve® in complex wound care

globenewswire.com

May 7

Kane Biotech Announces New Private Placement Offering

Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 07, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces its intention to undertake a non-brokered private placement offering (the “Offering”) of up to 20,000,000 units of the Company (“Units”) at a price of $0.05 per Unit for gross proceeds of up to $1,000,000. Each Unit shall be comprised of one common share of the Company (a “Share”) and one Share purchase warrant (a “Warrant”).

globenewswire.com

Apr 23

Kane Biotech Announces Fourth Quarter and Full Year 2025 Financial Results

WINNIPEG, Manitoba, April 23, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its fourth quarter and full year 2025 financial results.

globenewswire.com

Mar 17

Kane Biotech Announces Publication in Frontiers in Antibiotics Highlighting Advancements in Treating Antibiotic Tolerant Biofilms

WINNIPEG, Manitoba, March 17, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or “Kane”) announces that Frontiers in Antibiotics has published a peer-reviewed article authored by researchers from Kane Biotech and the University of Manitoba, detailing important scientific advancements in the fight against antibiotic-tolerant biofilms.

globenewswire.com

Mar 10

Kane Biotech Expands U.S. Commercial Footprint with Strategic Distribution Partnership

WINNIPEG, Manitoba, March 10, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (Kane or the Company), transforming wound care with three FDA 510(k) cleared and two Health Canada approved formats, is pleased to announce two significant expansions to its U.S. commercialization strategy as it prepares for nationwide growth of its advanced wound care portfolio, including the revyve® Antimicrobial Wound Gel. These strategic steps include the signing of a federally aligned distribution partnership to support entry into the U.S. Veterans Affairs (VA) market, the U.S. Department of Defense (DOD), and U.S. Indian Health Services (IHS) and the signing of multiple independent sales representative agreements.

Company Profile

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the DispersinB name; shampoos for dogs, cats, and horses under the Alosera name; and medical device coatings under the Aledex name. It also offers scalp care products under the DermaKB brand name, wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2007-08-07

Beta

0.25

Websitekanebiotech.com↗